Dr. Burris on the Utility of Sacituzumab Govitecan in Metastatic TNBC

Partner | Cancer Centers | <b>Sarah Cannon</b>

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses ​the utility of sacituzumab govitecan-hzi​y in metastatic triple-negative breast cancer.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, chief medical officer and president of Clinical Operations at Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses ​the utility of sacituzumab govitecan-hzi​y (Trodelvy) in metastatic triple-negative breast cancer (TNBC).

Since being granted accelerated approval on April 22, 2020, sacituzumab govitecan has been used safely and effectively in ​the clinical setting for this patient ​population, says Burris​. However, premedication with antiemetics is often necessary. 

Additionally, the agent has demonstrated several encouraging ​efficacy signals, such as improved liver function ​tests and cancer-related symptoms​, Burris explains.

Notably, the camptothecin toxin in sacituzumab govitecan has always been an agent of interest due to its active payload in irinotecan. ​As such, the mechanism of linking the toxin to an antibody suggests that patients will benefit significantly from this therapy, Burris concludes.